Evaluation of Clinical Perfectionism in Parkinson Disease

Parkinson Disease Clinical Trial

— EPMP-1  

Official title:

Evaluation of Clinical Perfectionism in Parkinson Disease

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02824367
• Other study ID #: PI2014_843_0002
• Secondary ID: 2013-A01302-43
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 6, 2014
• Est. completion date: August 2018

Study information

• Verified date: August 2018
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Scientific studies show that almost half of the people with Parkinson's Disease (PD) suffer of depression and / or anxiety.

Description:

Scientific studies show that almost half of the people with Parkinson's Disease (PD) suffer of depression and / or anxiety. Also, clinicians reported that they exhibit specific personality traits (e.g., rigidity and perfectionism).

To date, few studies used Cognitive Behavioural Therapies (CBT) in people with Parkinson's disease showing promising results. Recently, perfectionism has received particular attention because of it association with many emotional disorders. Thus, some psychometric tools have been developed in order to evaluate different aspects of perfectionism. Yet, none of them has been used in people with Parkinson's disease.

The objective of this study is to investigate whether there is a direct link between Parkinson's disease and perfectionism by using psychometric tools from the CBT literature. Identifying such link would allow to justify the use of CBT in people with Parkinson's disease with the goal in mind to improve their care and quality of life.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: August 2018
• Est. primary completion date: August 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age greater than 18 years

• Score Mini Mental Scale (MMS) greater than 23

• For Parkinsonian, Parkinson disease be defined according to the criteria of the Unified Parkinson Disease Rating Scale (UPDRS), with a Hoehn and Yahr stage 1, 2 or 3

• The control patients present dystonias not within the scope of Parkinson

• Informed Consent Form signed

• Patient covered by social insurance

Exclusion Criteria:

• Proven Presence of neuropsychological disorders

• Patients with deep brain stimulation

• Diagnosis of somatic pathology diagnosed

• Private Patient freedom or protected adult (under guardianship)

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Behavioral:
• Completion of scales evaluation
Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))

Locations

Country	Name	City	State
France	CHU Amiens	Amiens

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Perfectionism evaluation 1	Scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS)	Day 0
Primary	Perfectionism evaluation 2	Hewitt Multidimensional Perfectionism Scale (HMPS).	Day 0
Secondary	Depression and anxiety evaluation 1	Scores to depression scale (Beck Depression Inventory (BDI))	Day 0
Secondary	Depression and anxiety evaluation 2	anxiety scale (State Trait Anxiety Inventory (STAI))	Day 0